GrayMatters Health is a groundbreaking brand that is redefining mental health care. Their flagship product, Prism for PTSD, is the first neuromodulation procedure to receive FDA clearance as a prescribed adjunct therapy for post-traumatic stress disorder (PTSD). With their innovative approach, GrayMatters Health is revolutionizing the treatment of mental health disorders.

Prism utilizes a unique amygdala-derived biomarker technology, which enhances standard of care clinical outcomes for healthcare providers. By combining amygdala-fMRI-guided models with EEG neurofeedback, Prism allows patients to train themselves in downregulating the amygdala-derived-EFP biomarker in real-time. Unlike traditional EEG neurofeedback, Prism can measure deep brain regions, making it a game-changer in the field.

GrayMatters Health's cutting-edge technology is backed by extensive research and clinical trials, with publications in prestigious medical journals showcasing its effectiveness. With Prism for PTSD as their first-to-market solution, GrayMatters Health aims to address the unmet needs of the approximately 250 million people worldwide living with PTSD.

This visionary brand is committed to improving the lives of individuals with mental health disorders and is poised to make a lasting impact in the field.